| Pharmacokinetic and pharmacodynamic data analysis: concepts and applications J Gabrielsson, D Weiner CRC press, 2001 | 1379 | 2001 |
| Non-compartmental analysis J Gabrielsson, D Weiner Computational Toxicology: Volume I, 377-389, 2012 | 351 | 2012 |
| Cardiovascular Properties of a New Cardiotonic Agent: MDL 17,043 (1, 3-Dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2: H:-imidazol-2-one) RC Dage, LE Roebel, CP Hsieh, DL Weiner, JK Woodward Journal of Cardiovascular Pharmacology 4 (3), 500-508, 1982 | 131 | 1982 |
| Precision dosing priority criteria: drug, disease, and patient population variables RJ Tyson, CC Park, JR Powell, JH Patterson, D Weiner, PB Watkins, ... Frontiers in pharmacology 11, 420, 2020 | 104 | 2020 |
| Bioavailability of terfenadine in man RA Okerholm, DL Weiner, RH Hook, BJ Walker, GA Leeson, ... Biopharmaceutics & Drug Disposition 2 (2), 185-190, 1981 | 73 | 1981 |
| Drug Dosing Recommendations for All Patients: A Roadmap for Change D Powell, J., Cook, J., Wang, Y., Peck, R., Weiner Clinical Pharmacology & Therapeutics, 2020 | 43* | 2020 |
| The future of the pharmaceutical sciences and graduate education: Recommendations from the AACP Graduate Education Special Interest Group S Wu-Pong, J Gobburu, S O’Barr, K Shah, J Huber, D Weiner American Journal of Pharmaceutical Education 77 (4), S2, 2013 | 33 | 2013 |
| Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses BD Hamamoto‐Hardman, EP Steffey, D Weiner, DS McKemie, P Kass, ... Journal of veterinary pharmacology and therapeutics 42 (4), 401-410, 2019 | 32 | 2019 |
| Design and analysis of bioavailability studies DL Weiner Statistics in the pharmaceutical industry, 205-229, 1981 | 32 | 1981 |
| Pharmacokinetic and pharmacodynamic data analysis J Gabrielson, D Weiner Concept and Application, 1994 | 28 | 1994 |
| Pattern recognition in pharmacokinetic data analysis J Gabrielsson, B Meibohm, D Weiner The AAPS journal 18, 47-63, 2016 | 26 | 2016 |
| Antihypertensive and adrenergic receptor blocking properties of the enantiomers of medroxalol HC Cheng, OK Reavis Jr, JM Grisar, GP Claxton, DL Weiner, ... Life Sciences 27 (25-26), 2529-2534, 1980 | 25 | 1980 |
| Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes SJ Balevic, D Weiner, MEB Clowse, AM Eudy, AR Maharaj, CP Hornik, ... Lupus Science & Medicine 9 (1), e000602, 2022 | 21 | 2022 |
| Rivaroxaban precision dosing strategy for real‐world atrial fibrillation patients R Konicki, D Weiner, J Herbert Patterson, D Gonzalez, A Kashuba, ... Clinical and Translational Science 13 (4), 777-784, 2020 | 18 | 2020 |
| Pharmacokinetic and Pharmacodynamic Analysis: Concepts and Applications, Swedish Pharmaceutical Society J Gabrielsson, D Weiner Swedish Pharmaceutical Press, Stockholm, Sweden 1997, 1997 | 16 | 1997 |
| A simulation study of parameter estimation in the one and two compartment models PM Laskarzewski, DL Weiner, L Ott Journal of Pharmacokinetics and Biopharmaceutics 10 (3), 317-334, 1982 | 15 | 1982 |
| Serum concentrations, pharmacokinetic/pharmacodynamic modeling, and effects of dexamethasone on inflammatory mediators following intravenous and oral administration to … HK Knych, D Weiner, RM Arthur, R Baden, DS McKemie, PH Kass Drug testing and analysis 12 (8), 1087-1101, 2020 | 13 | 2020 |
| Modeling strategies J Gabrielsson, D Weiner Pharmacokinetic and Pharmacodynamic Analysis: Concepts and Applications, 460, 2000 | 12 | 2000 |
| The pharmacokinetics of a new cardiotonic agent, MDL 19205, 4-ethyl-1, 3-dihydro-5-(4-pyridinyl)-2H-imidazol-2-one (abstr) RA Okerholm, FJ Keeley, DL Weiner, RB Spangenberg Fed Proc 42, 1131, 1983 | 11 | 1983 |
| A real‐world evidence framework for optimizing dosing in all patients with COVID‐19 RW Peck, D Weiner, J Cook, J Robert Powell Clinical Pharmacology & Therapeutics 108 (5), 921-923, 2020 | 9 | 2020 |
Daniel GonzalezDuke Universityایمیل تأیید شده در duke.edu
